Sumitomo Dainippon Pharma Co Ltd (4506) - Financial and Strategic SWOT Analysis Review
July 2019
61
About the Report
About the Report
Sumitomo Dainippon Pharma Co Ltd (4506)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description-A detailed description of the company's operations and business divisions.
- Corporate strategy-Analyst's summarization of the company's business strategy.
- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history-Progression of key events associated with the company.
- Major products and services-A list of major products, services and brands of the company.
- Key competitors-A list of key competitors to the company.
- Key employees-A list of the key executives of the company.
- Executive biographies-A brief summary of the executives' employment history.
- Key operational heads-A list of personnel heading key departments/functions.
- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities-A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Sumitomo Dainippon Pharma Co Ltd (Sumitomo Dainippon), a subsidiary of Sumitomo Chemical Co Ltd develops manufactures, purchases, sells, imports and exports pharmaceutical products. The company focuses on major therapeutic areas which include central nervous system (CNS), cardiovascular, diabetes, oncology, respiratory psychiatry and neurology and infectious diseases. It also offers veterinary products, research materials, food additives, chemical product materials, food ingredients, diagnostic agents, cosmetic materials and other products. Sumitomo Dainippon has research laboratories, manufacturing and distribution facilities in Japan. The company operates through subsidiaries and offices in the North America, Europe and Asia Pacific. Sumitomo Dainippon is headquartered in Chuo-ku, Osaka, Japan.
Sumitomo Dainippon Pharma Co Ltd Key Recent Developments
May 10,2019: Sumitomo Dainippon Pharma announces Changes in Board of Directors
May 08,2019: Sumitomo Dainippon Pharma to Open a New Office for its Regenerative Medicine/Cell Therapy Business in San Diego, U.S.
Apr 11,2019: Sumitomo Dainippon Pharma announces mid-term business plan 2022
Mar 04,2019: Sumitomo Dainippon Pharma expands roles and responsibilities of subsidiary in Singapore and establishes subsidiary in Thailand
Oct 30,2018: Sumitomo Dainippon: Consolidated financial results for the second quarter of the year ending March 31, 2019
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Products
Products
Sumitomo Dainippon Pharma Co Ltd, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts
Companies
Tsumura & co
Towa Pharmaceutical Co Ltd
Torii Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
Shin-Etsu Chemical Co Ltd
Shin Nippon Biomedical Laboratories Ltd
Nippon Shinyaku Co Ltd
Mochida Pharmaceutical Co Ltd
Mitsubishi Tanabe Pharma Corp
Kissei Pharmaceutical Co Ltd
Chugai Pharmaceutical Co Ltd
Astellas Pharma Inc
Table of Contents
Table of Contents
Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1-About the Company
Sumitomo Dainippon Pharma Co Ltd-Key Facts
Sumitomo Dainippon Pharma Co Ltd-Key Employees
Sumitomo Dainippon Pharma Co Ltd-Key Employee Biographies
Sumitomo Dainippon Pharma Co Ltd-Major Products and Services
Sumitomo Dainippon Pharma Co Ltd-History
Sumitomo Dainippon Pharma Co Ltd-Company Statement
Sumitomo Dainippon Pharma Co Ltd-Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2-Company Analysis
Company Overview
Sumitomo Dainippon Pharma Co Ltd-Business Description
Business Segment: Other Business
Overview
Performance
Business Segment: Pharmaceuticals Business
Overview
Performance
Geographical Segment: China
Performance
Geographical Segment: Japan
Performance
Geographical Segment: North America
Performance
Geographical Segment: Other Regions
Performance
R&D Overview
Sumitomo Dainippon Pharma Co Ltd-SWOT Analysis
SWOT Analysis-Overview
Sumitomo Dainippon Pharma Co Ltd-Strengths
Sumitomo Dainippon Pharma Co Ltd-Weaknesses
Sumitomo Dainippon Pharma Co Ltd-Opportunities
Sumitomo Dainippon Pharma Co Ltd-Threats
Sumitomo Dainippon Pharma Co Ltd-Key Competitors
Section 3-Company Financial Ratios
Financial Ratios-Capital Market Ratios
Financial Ratios-Annual Ratios
Performance Chart
Financial Performance
Financial Ratios-Interim Ratios
Financial Ratios-Ratio Charts
Section 4-Company's Lifesciences Financial Deals and Alliances
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Sumitomo Dainippon Pharma Co Ltd, Recent Deals Summary
Section 5-Company's Recent Developments
May 10, 2019: Sumitomo Dainippon Pharma announces Changes in Board of Directors
May 08, 2019: Sumitomo Dainippon Pharma to Open a New Office for its Regenerative Medicine/Cell Therapy Business in San Diego, U.S.
Apr 11, 2019: Sumitomo Dainippon Pharma announces mid-term business plan 2022
Mar 04, 2019: Sumitomo Dainippon Pharma expands roles and responsibilities of subsidiary in Singapore and establishes subsidiary in Thailand
Oct 30, 2018: Sumitomo Dainippon: Consolidated financial results for the second quarter of the year ending March 31, 2019
Sep 27, 2018: Sumitomo Dainippon Pharma receives the award of Gold Class in Overall Category of SUSTAINA ESG AWARD 2018
Sep 27, 2018: Sumitomo Dainippon Pharma selected as a component of Dow Jones Sustainability Indices DJSI for the second Consecutive Year
Sep 03, 2018: Sumitomo Dainippon Pharma announces personnel changes
Jul 30, 2018: Kyoto University Hospital and the Center for iPS Cell Research and Application (CiRA) to begin physician-initiated clinical trials for parkinson's disease
Jul 27, 2018: Sumitomo Dainippon Pharma provides summary of consolidated financial results for the first quarter of the year ending March 31, 2019
Section 6-Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Figure
List of Figures
Sumitomo Dainippon Pharma Co Ltd, Performance Chart (2015-2019)
Sumitomo Dainippon Pharma Co Ltd, Ratio Charts
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
List of Table
List of Tables
Sumitomo Dainippon Pharma Co Ltd, Key Facts
Sumitomo Dainippon Pharma Co Ltd, Key Employees
Sumitomo Dainippon Pharma Co Ltd, Key Employee Biographies
Sumitomo Dainippon Pharma Co Ltd, Major Products and Services
Sumitomo Dainippon Pharma Co Ltd, History
Sumitomo Dainippon Pharma Co Ltd, Other Locations
Sumitomo Dainippon Pharma Co Ltd, Subsidiaries
Sumitomo Dainippon Pharma Co Ltd, Key Competitors
Sumitomo Dainippon Pharma Co Ltd, Ratios based on current share price
Sumitomo Dainippon Pharma Co Ltd, Annual Ratios
Sumitomo Dainippon Pharma Co Ltd, Annual Ratios (Cont...1)
Sumitomo Dainippon Pharma Co Ltd, Annual Ratios (Cont...2)
Sumitomo Dainippon Pharma Co Ltd, Interim Ratios
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Sumitomo Dainippon Pharma Co Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Why Buy From US?
![RRR](images/data-analysis.webp)
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
![reach](images/social-reach.webp)
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
![Research](images/monitoring.webp)
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
![Insite](images/insight.webp)
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
![Trust](images/guarantee.webp)
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
![support](images/customer-care.webp)
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.